Chronic lymphocytic leukemia (CLL) may be associated with immune thrombocytopenia (ITP). The standard treatment for CLL-associated ITP is steroids. For refractory cases, various treatment strategies such as rituximab, splenectomy, and thrombopoietic mimetics are available. We report a patient with CLL who developed recurrent ITP and life-threatening pulmonary hemorrhage. Platelet counts remained extremely low despite massive platelet transfusion and treatment including steroids, immunoglobulin, and single-dose rituximab infusion. The bleeding stopped and platelet counts were increased to normal range 13 days after treatment with eltrombopag 25 mg per day. Our experience suggests that eltrombopag is an effective treatment option in CLL-associated, refractory ITP, especially during major bleeding, which requires relatively rapid improvement of thrombocytopenia.
Tumori 2015; 101(2): e49 - e50
Article Type: CASE REPORT
AuthorsHung Chang, Lee-Yung Shih
- • Accepted on 20/03/2014
- • Available online on 19/02/2015
- • Published online on 28/04/2015
This article is available as full text PDF.
- Chang, Hung [PubMed] [Google Scholar] 1, 2, * Corresponding Author (firstname.lastname@example.org)
- Shih, Lee-Yung [PubMed] [Google Scholar] 1, 2
School of Medicine, Chang Gung University, Kweishan Township, Taoyuan - Taiwan
Division of Hematology-Oncology, Chang Gung Memorial Hospital, Kweishan Township, Taoyuan - Taiwan